compound semaglutide hims Despite the Stigma, & Hers Isn't Backing Away From Weight-Loss Drugs Hims & Hers CEO hits

A patient might be cautious of increasing semaglutide from 0.25 to 0.5 mg, so we might discuss microdosing to achieve a dose in between, says Tchang

It means obesity and weight regain should be managed as chronic medical risks, not as a one-time diet project

Mortality and major adverse cardiac events (MACE) with GLP-1 receptor agonists in psoriatic arthritis

It may relate to population differences or shorter trial duration

These gray-market products are completely untested for human safety, highly prone to contamination, and illegal to buy or sell for personal use

The future of GLP-1 dosing The dosing landscape is evolving rapidly